AMBICION develops new drugs focused on establishing a global standard treatment for cancer patients. The company's is called product Natural killer T cells or NKT cells, a type of T cells that also have NK cell properties. It is activated by recognizing glycolipid antigens, produce many types of cytokines, and induce both immunostimulation and suppression reactions. NKT cells can induce cell death to cancer cells due to the nature of NK cells, but its direct cytotoxic activity is limited due to the small amount present in the body. NKT cells also have the ability to produce large amounts of cytokines. AMBICION was founded in October 2015 and is headquartered in Tokyo, Japan.
| Website | http://www.ambicion.co.jp |
| Revenue | $2 million |
| Employees | View employees |
| Founded | 2015 |
| Address | 2 6 Shinjuku-ku Wako Bldg 5F, Tokyo, Tokyo, JP |
| Phone | +81 3-5357-7231 |
| Industry | Chemicals, Petrochemicals, Glass & Gases, Health Care, Manufacturing, Medical, Product Research, Data and Analytics, Design, Wellness |
| Competitors | MUFG Securities Americas Inc., Citibank, SBI Securities, Sompo Japan Insurance Inc., Daiwa Securities, Rakuten Securities, Inc., （株）みずほフィナンシャルグループ, （株）千葉銀行, The Bank of Fukuoka, Ltd., 野村ホールディングス（株） +38 more (view full list) |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325414 Companies, NAICS Code 32 Companies |
Looking for a particular AMBICION employee's phone or email?
AMBICION Questions
The AMBICION annual revenue was $2 million in 2026.
AMBICION is based in Tokyo, Tokyo.
The NAICS codes for AMBICION are [325, 32541, 3254, 325414, 32].
The SIC codes for AMBICION are [283, 28].
